Biotech Values

[Double_Bagel]

Credit Suisse on Clovis

http://online.barrons.com/news/articles/SB50001424053111904255004580037790574691662

Clovis (rated at Outperform, $100 target price) is currently not an earnings-driven story. The spotlight remains on CO-1686 as a treatment for first-line epidermal growth factor receptor mutations (EGFRm+) and second-line EGFRm-T790M+ non-small cell lung cancer (NSCLC). Patient identifiable (PI) data presented at the American Society of Clinical Oncology (ASCO) meeting showed that CO-1686 and [AstraZeneca's (AZN)] AZD9291's efficacy was highly comparable. Safety was the key focus with the street positioning AZD9291 having a cleaner safety profile than CO-1686. The call may provide management to expand the insulin-like growth factor 1 receptor (IGF1R) hypothesis. We anticipate additional attention on: 1) updates on Lucitinib phase II trials in advanced breast cancer (FGFR1-amp, 11q-amp, FGF-WT) and squamous NSCLC (FGFR1-amp); 2) updates on ARIEL2 phase II biomarker trial and ARIEL3 phase III trial both for Rucaparib in platinum-sensitive, relapsed ovarian cancer.